Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment by Michael Weichenthal, Inge Marie Svane, Johanna Mangana, Ulrike Leiter, Friedegund Meier, Christina Ruhlmann, Dimitrios Ziogas, Reinhard Dummer, Pablo Cerenzuela, Jose Luis Manzano, Marc Bender, Shan Jiang, Paolo Antonio Ascierto, Iva Gavrilova, Lidija Kandolf, Helen Gogas, Peter Mohr, Dirk Schadendorf, Eva Ellebaek

Get full text

Impact of osteoprotective therapies on the efficacy of immune checkpoint inhibition in melanoma patients – A multicentre study from the prospective skin cancer registry ADOReg by Corinna Kochanek, Katrin Schaper-Gerhardt, Lisa Zimmer, Selma Ugurel, Friedegund Meier, Peter Mohr, Patrick Terheyden, Sebastian Haferkamp, Martin Kaatz, Michael Sachse, Frank Meiss, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Dirk Schadendorf, Michael Weichenthal, Imke von Wasielewski, Yenny Angela, Ralf Gutzmer

Get full text

German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023 by Ulrike Leiter, Markus V. Heppt, Theresa Steeb, Mareike Alter, Teresa Amaral, Andrea Bauer, Falk G. Bechara, Jürgen C. Becker, Eckhard W. Breitbart, Helmut Breuninger, Thomas Diepgen, Thomas Dirschka, Thomas Eigentler, A.K. Stephan El Gammal, Moritz Felcht, Michael J. Flaig, Markus Follmann, Klaus Fritz, Stephan Grabbe, Rüdiger Greinert, Ralf Gutzmer, Axel Hauschild, Uwe Hillen, Stephan Ihrler, Swen Malte John, Lukas Kofler, Oliver Koelbl, Albrecht Krause-Bergmann, Klaus Kraywinkel, Steffen Krohn, Thomas Langer, Carmen Loquai, Christoph R. Löser, Peter Mohr, Dorothée Nashan, Monika Nothacker, Christina Pfannenberg, Carmen Salavastru, Lutz Schmitz, Eggert Stockfleth, Rolf-Markus Szeimies, Claas Ulrich, Susanne Voelter-Mahlknecht, Dirk Vordermark, Michael Weichenthal, Julia Welzel, Kai Wermker, Susanne Wiegand, Claus Garbe, Carola Berking

Get full text